Mapping immunotherapy opportunity in APACs
=============================================

The main focus of this notebook is to map the immunotherapy opportunity in APACs.

## Objectives

1. Identify and catalog procedures associated with immunotherapy.
2. Search procedures in APAC-AQ and APAC-AM.
3. Create metrics for:
    - Total number of APACs
    - Total number of patiencs (CNS)
    - Total value of APACs.

## Results

The analysis revealed 23 procedures associated with immunotherapy medications.

| Procedure |
| --- |
| ADALIMUMABE 40 MG INJETAVEL (POR SERINGA PREENCHIDA) |
| INFLIXIMABE 10 MG/ML INJETAVEL (POR FRASCO-AMPOLA COM 10 ML) |
| TOFACITINIBE 5 MG (POR COMPRIMIDO) |
| TOCILIZUMABE 20 MG/ML INJETAVEL (POR FRASCO-AMPOLA DE 4 ML) |
| INFLIXIMABE 10 MG /ML INJETAVEL (POR FRASCO-AMPOLA COM 10 ML) (BIOSSIMILAR A) |
| ADALIMUMABE 40 MG INJETAVEL ( POR SERINGA PREENCHIDA)( BIOSSIMILAR A) |
| VEDOLIZUMABE 300 MG PO LIOFILIZADO PARA SOLUCAO INJETAVEL |
| BARICITINIBE 4MG (POR COMPRIMIDO) |
| RITUXIMABE 500 MG INJETAVEL (POR FRASCO- AMPOLA DE 5O ML ) (BIOSSIMILAR A) |
| UPADACITINIBE 15 MG (POR COMPRIMIDO REVESTIDO DE LIBERACAO PROLONGADA) |
| OMALIZUMABE 150MG SOLUCAO INJETAVEL |
| ADALIMUMABE 40 MG INJETAVEL (POR SERINGA PREENCHIDA) (BIOSSIMILAR B) |
| RITUXIMABE 500 MG INJETAVEL (POR FRASCO-AMPOLA DE 50 ML) (ORIGINADOR) |
| RITUXIMABE 500 MG INJETAVEL (POR FRASCO AMPOLA DE 50 ML(BIOSSIMILAR B) |
| BARICITINIBE 2MG (POR COMPRIMIDO) |
| ADALIMUMABE 40 MG INJETAVEL (FRASCO AMPOLA) |
| ALENTUZUMABE 10 MG/ML SOLUCAO INJETAVEL (FRASCO-AMPOLA CONTENDO 1,2 ML) |

No records of APACs were identified within the `APAC-AQ` dataset.

For `APAC-AM`, we identified 17 procedures associated with immunotherapy drugs, which were narrowed down to 10 distinct drugs, corresponding to 936,696 records.


| drug            | Total number of APACs | Total number of patients | Total value of APACs  |
|-----------------|---------------------:|------------------------:|----------------------:|
| ADALIMUMABE     | 566,630              | 66,993                  | R$ 19,926.40        |
| INFLIXIMABE     | 177,110              | 24,935                  | R$ 0.00             |
| TOFACITINIBE    | 90,594               | 11,782                  | R$ 0.00             |
| TOCILIZUMABE    | 62,162               | 7,767                   | R$ 0.00             |
| RITUXIMABE      | 10,249               | 2,937                   | R$ 0.00             |
| VEDOLIZUMABE    | 10,208               | 1,867                   | R$ 0.00             |
| BARICITINIBE    | 8,126                | 1,598                   | R$ 0.00             |
| UPADACITINIBE   | 6,551                | 2,416                   | R$ 0.00             |
| OMALIZUMABE     | 5,057                | 961                     | R$ 27,744,064.64    |
| ALENTUZUMABE    | 9                   | 7                       | R$ 0.00             |
| **TOTAL**       | **936,696**          | **118,589**             | **R$ 27,763,991.04** |